Sanofi has become the latest Big Pharma to freeze R&D investment decisions in the U.K., while Roche confirmed it is staying put—for now. The news that Sanofi won’t consider “any substantial investment” in medicines R&D in the U.K. for the time being continues the fallout from tricky drug pricing negotiations that saw the nation’s health minister walk away from talks with the industry body late last month. Source: Fierce Biotech 15/9/2025